GlassScriptPhysician profile
Taras Benzar
NPI 1861924391
$7,909.77
in general payments reported to CMS, 2019-2025
56 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $224 · 2021: $151 · 2022: $333 · 2023: $1,311 · 2024: $3,867 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,762 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,762.02 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,756.36 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $454.85 | 2021-2025 | Enhertu, Imfinzi, Tagrisso |
| Eisai INC. | $447.68 | 2020-2025 | |
| Daiichi Sankyo INC. | $426.87 | 2022-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $385.01 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $334.33 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $330.90 | 2023-2025 | |
| Janssen Biotech, INC. | $228.39 | 2024-2025 | Rybrevant, Erleada, Talvey |
| Abbvie INC. | $220.22 | 2024-2025 | |
| Stemline Therapeutics INC. | $217.30 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $211.26 | 2021-2024 | Tecentriq, Phesgo, Tecentriq Hybreza |
| Astellas Pharma US INC | $204.39 | 2023-2025 | Xtandi, Padcev, Vyloy |
| Glaxosmithkline, LLC. | $174.83 | 2022-2024 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $169.33 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $159.20 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $151.18 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Adaptive Biotechnologies Corporation | $126.72 | 2025 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $114.49 | 2023-2025 | Fruzaqla, Ninlaro |
| Caris Mpi, INC. | $106.77 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $106.56 | 2022-2024 | Libtayo |
| Gilead Sciences, INC. | $104.40 | 2024 | |
| Amgen INC. | $99.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $95.61 | 2023-2024 | Ultomiris |
| Array Biopharma INC | $86.80 | 2024 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $86.16 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Blueprint Medicines Corporation | $84.93 | 2024 | Ayvakit |
| Puma Biotechnology, INC. | $59.69 | 2023-2024 | |
| Exelixis INC. | $58.97 | 2023 | Cabometyx |
| Jazz Pharmaceuticals INC. | $57.68 | 2024 | |
| Progenics Pharmaceuticals, INC. | $56.41 | 2024 | |
| Genzyme Corporation | $55.06 | 2024 | |
| Beigene USA, INC. | $47.87 | 2023-2024 | Brukinsa |
| Sobi, INC | $46.09 | 2022-2024 | |
| Mirati Therapeutics, INC. | $45.16 | 2023-2024 | Krazati |
| Coherus Oncology, INC. | $43.80 | 2024 | |
| Tersera Therapeutics LLC | $43.31 | 2022-2023 | Zoladex |
| Seagen INC. | $38.91 | 2023 | Padcev, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $38.28 | 2023 | Imbruvica, Epkinly |
| Novocure INC. | $38.21 | 2025 | Optune Lua (Novottf-200t) |
| Sumitomo Pharma America, INC. | $37.15 | 2023-2024 | Orgovyx |
| Emd Serono, INC. | $34.27 | 2024 | |
| Aveo Pharmaceuticals, INC. | $30.92 | 2025 | |
| Adc Therapeutics America, INC. | $29.56 | 2024 | |
| Apellis Pharmaceuticals, INC. | $28.26 | 2024 | Empaveli |
| Springworks Therapeutics, INC. | $26.34 | 2024 | Ogsiveo |
| Morphosys, US INC. | $24.65 | 2024 | Monjuvi |
| Lilly USA, LLC | $22.55 | 2025 | Verzenio, Jaypirca |
| Pharmaessentia USA Corporation | $21.46 | 2024 | Besremi |
| Servier Pharmaceuticals LLC | $21.17 | 2024 | |
| Immunogen, INC. | $20.25 | 2024 | Elahere |
| Kyowa Kirin, INC. | $18.83 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.22 | 2024 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $16.93 | 2024 | |
| Emmaus Medical, INC. | $16.89 | 2023 | Endari |
| Chiesi USA, INC. | $16.01 | 2024 | Ferriprox |
| Taiho Oncology, INC. | $13.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taras Benzar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.